A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Inclusion Criteria:

• Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).
• Subject has Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
• Subject has a new clinical or pathologic diagnosis of resectable HPV+ or HPV- SCCHN ofthe oral cavity, pharynx, or larynx
• Macroscopic complete resection of the primary tumor must be planned and subjectsshould have no medical contraindication to surgery.
• Subject consents to and has tumor accessible for tumor biopsy pre-treatment.
• Subjects must have acceptable hematopoietic, liver, renal, and coagulation function asassessed by laboratory tests.

Exclusion Criteria:

• Subject has any significant medical condition, laboratory abnormality, or psychiatricillness that would prevent the subject from participating in the study
• Subject has unresectable or inoperable tumors
• Subject has primary tumors of the sinuses, paranasal sinuses, or nasopharynx, orunknown primary tumors
• Subject has evidence of distant metastasis
• Subject is a pregnant or nursing female.
• Subject has active or uncontrolled infection including known HIV infection or knownchronic hepatitis B or C.
• Subject has active autoimmune disease.
• Subject has clinically significant ophthalmologic disease.